Literature DB >> 17890895

Precursor lesions of the adrenal gland.

F H van Nederveen1, R R de Krijger.   

Abstract

OBJECTIVE: To review the existing literature for evidence that adrenocortical and adrenomedullary tumours develop through a multistep process of carcinogenesis.
RESULTS: In the adrenal cortex hyperplasia and adenomas are frequently observed tumours or tumour-like conditions. In contrast, adrenocortical carcinomas are rare. Based on well-validated histopathological scoring systems, benign and malignant adrenocortical tumours can be separated, although a small subset of tumours remains hard to classify. Although extensive follow-up studies might argue against multistep carcinogenesis, analysis of chromosomal imbalances and gene expression profiling studies in these tumours are inconclusive and could give support for both multistep pathogenesis or de novo genesis of carcinomas. A major limit to most of these studies is the small sample size and the lack of extensive clinical (follow-up) data. In the adrenal medulla, pheochromocytomas (PCC) are the most frequent tumours in adults, with an incidence of 8 per million. They can be divided into benign and malignant PCC, but the distinction can only be made when metastases are present. Arbitrarily, lesions of less than 1 cm in diameter are called hyperplastic, but it should be expected that the majority of these are early lesions and if left in situ would grow to classify as PCC. In contrast to cortical tumours, the frequent 1p and 3q loss as an early event in tumourigenesis of benign PCC is verified in multiple studies. However, studies in malignant PCC yield divergent results, due to the small numbers analysed.
CONCLUSION: Taken together, there appears to be a relationship between cortical and medullary hyperplasia on the one hand and cortical adenomas and PCC on the other. However, whether there is a transition from benign to malignant tumours, both cortical and medullary, remains to be determined. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2007        PMID: 17890895     DOI: 10.1159/000105811

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  4 in total

Review 1.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

2.  Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis.

Authors:  Levent Ozsari; Merve Kutahyalioglu; Khaled M Elsayes; Rafael Andres Vicens; Kanishka Sircar; Tarek Jazaerly; Steven G Waguespack; Naifa L Busaidy; Maria E Cabanillas; Ramona Dadu; Mimi I Hu; Rena Vassilopoulou-Sellin; Camilo Jimenez; Jeffrey E Lee; Mouhammed Amir Habra
Journal:  Endocrine       Date:  2015-07-25       Impact factor: 3.633

3.  Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome.

Authors:  Esther Korpershoek; Bart-Jeroen Petri; Edward Post; Casper H J van Eijck; Rogier A Oldenburg; Eric J T Belt; Wouter W de Herder; Ronald R de Krijger; Winand N M Dinjens
Journal:  Neoplasia       Date:  2014-10-23       Impact factor: 5.715

Review 4.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.